IMMUCON

Immucon is a South Korean biotechnology company specializing in the development of next-generation vaccines and immunotherapies for infectious diseases and oncology. The company leverages its proprietary "Immucon" platform, which utilizes immune-modulating conjugates to link antigens with potent adjuvants, thereby enhancing the immune response while minimizing systemic toxicity. Its lead candidate, IMC-001, is a recombinant protein vaccine for COVID-19 that has entered clinical development. Immucon is also advancing a pipeline of therapeutic cancer vaccines and novel adjuvant systems, including TLR7/8 and TLR4 agonists, aimed at improving treatment outcomes for various solid tumors. The company's approach focuses on optimizing the delivery and presentation of antigens to the immune system to create more effective prophylactic and therapeutic solutions.